SCHEMBL662274

SCHEMBL662274

O=C1Cc2ccccc2N1Cn1ccnc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 8/20 0.43
HTR1A P08908 4/20 0.43
CYP17A1 P05093 1/20 0.42
TBXAS1 P24557 2/20 0.41
CYP1A2 P05177 1/20 0.41
POLB P06746 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
MAPT P10636 1/20 0.41
CYP19A1 P11511 1/20 0.41
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
QPCT Q16769 1/20 0.41
CYP4Z1 Q86W10 1/20 0.41
QPCTL Q9NXS2 1/20 0.41
DRD2 P14416 2/20 0.40
DRD5 P21918 1/20 0.40
DRD3 P35462 1/20 0.40
DRD4 P21917 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29869045 1.00 HTR7 (0.43) HTR7HTR1ACYP17A1TBXAS1CYP1A2
SCHEMBL10643087 0.82 HTR2A (0.46) HTR7HTR1ACYP17A1TBXAS1CYP1A2
SCHEMBL663325 0.81 CYP11B1 (0.41) TBXAS1CYP19A1CYP11B1CYP11B2
SCHEMBL660244 0.81 ADRA2C (0.42) TBXAS1CYP19A1CYP11B1CYP11B2
SCHEMBL661401 0.81 CYP11B1 (0.41) TBXAS1CYP1A2POLBCYP3A4CYP2D6
SCHEMBL29868527 0.81 CYP11B1 (0.41) TBXAS1CYP1A2POLBCYP3A4CYP2D6
SCHEMBL29868170 0.79 ALDH1A1 (0.39) TBXAS1CYP1A2POLBCYP3A4CYP2D6
SCHEMBL662426 0.79 ALDH1A1 (0.39) TBXAS1CYP1A2POLBCYP3A4CYP2D6
SCHEMBL661303 0.79 CYP11B1 (0.38) TBXAS1CYP19A1CYP11B1CYP11B2QPCT
SCHEMBL29868202 0.79 CYP11B1 (0.38) TBXAS1CYP19A1CYP11B1CYP11B2QPCT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1706376-B1 IMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB PHARMA SA (BE) 2009-03-04 EP claimed
US-20080081832-A1 Imidazole derivatives, processes for preparing them and their uses UCB, S.A. 2008-04-03 US claimed
JP-2007513105-A 2007-05-24 JP claimed
CN-1906160-A Imidazole derivatives, processes for preparing them and their uses UCB SA (BE) 2007-01-31 CN claimed
EP-1706376-A1 IMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2006-10-04 EP claimed
US-20050137241-A1 Imidazole derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2005-06-23 US claimed
WO-2005054188-A1 IMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2005-06-16 WO claimed
US-20240293363-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION UNIV JOHNS HOPKINS (US) 2024-09-05 US disclosed
US-20230277501-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2023-09-07 US disclosed
US-20230033195-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2023-02-02 US disclosed
US-20220265685-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2022-08-25 US disclosed
US-20220218665-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION UNIV JOHNS HOPKINS (US) 2022-07-14 US disclosed
US-11160785-B2 Methods and compositions for improving cognitive function AGENEBIO INC. (US) 2021-11-02 US disclosed
EP-1706376-B1 IMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB PHARMA SA (BE) 2009-03-04 EP disclosed
US-20080081832-A1 Imidazole derivatives, processes for preparing them and their uses UCB, S.A. 2008-04-03 US disclosed
US-7244747-B2 Imidazole derivatives, processes for preparing them and their uses UCB, S.A. (BE) 2007-07-17 US disclosed
CN-1906160-A Imidazole derivatives, processes for preparing them and their uses UCB SA (BE) 2007-01-31 CN disclosed
EP-1706376-A1 IMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2006-10-04 EP disclosed
US-20050137241-A1 Imidazole derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2005-06-23 US disclosed
WO-2005054188-A1 IMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2005-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11160785-B2 Methods and compositions for improving cognitive function BACE2, BACE1, GRIN2A HTR7 769/4885HTR1A 291/4885CYP17A1 1515/4885
US-20240293363-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE2, RAB2A, VAMP8 HTR7 1889/4885HTR1A 1290/4885CYP17A1 1965/4885
US-20220218665-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE2, RAB2A, VAMP8 HTR7 1889/4885HTR1A 1290/4885CYP17A1 1965/4885
US-20230277501-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION GRIN2A, CHRNA2, SYNGR2 HTR7 1636/4885HTR1A 595/4885CYP17A1 1208/4885
US-20220265685-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE1, BACE2, ACHE HTR7 1259/4885HTR1A 360/4885CYP17A1 2156/4885
US-20080081832-A1 Imidazole derivatives, processes for preparing them and their uses CYP3A4, PPIP5K2, CYP2C19 HTR7 404/4885HTR1A 1204/4885CYP17A1 1468/4885
US-20230033195-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION GRIN2D, GRIN2A, SLC18A2 HTR7 1571/4885HTR1A 1282/4885CYP17A1 2364/4885
US-20050137241-A1 Imidazole derivatives, processes for preparing them and their uses CYP3A4, PPIP5K2, CYP2C19 HTR7 404/4885HTR1A 1204/4885CYP17A1 1468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.